Innovent Biologics reports first participant dosed in tigulixostat Phase 3 study
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
Humacyte prices USD20m registered direct offering
Curia expands Glasgow manufacturing capacity and enhances CLD platform
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Mirecule expands collaboration with Sanofi to advance FSHD therapy
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics
Apertura Gene Therapy agrees manufacturing collaboration with Viralgen
Humacyte submits Israel MAA for Symvess arterial trauma repair
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment